Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade

Modern Pathology

Volumn 20, Issue 1, 2007, Pages 84-89

  Makretsov, Nikita A ^a,c,d   Hayes, Malcolm ^b   Carter, Beverley A ^c   Dabiri, Shahriar ^a   Gilks, C Blake ^a   Huntsman, David G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d Health Care Corporation of St John's   (Canada)

Author keywords

Breast; CD10; Invasive carcinoma; Prognosis; Stroma

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CARCINOMA IN SITU; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM EXPOSURE; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROMA CELL; SURVIVAL; TISSUE MICROARRAY; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; EXTRACELLULAR MATRIX; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEPRILYSIN; PROGNOSIS; RECEPTORS, ESTROGEN; STROMAL CELLS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845699283     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800713     Document Type: Article

References (21)

1. Albrecht M, Gillen S, Wilhelm B, et al. Expression, localization and activity of neutral endopeptidase in cultured cells of benign prostatic hyperplasia and prostate cancer. J Urol 2002;168:336-342.
2. Iwaya K, Ogawa H, Izumi M, et al. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002;440:589-593.
3. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004;17:646-652.
4. Ogawa H, Iwaya K, Izumi M, et al. Expression of CD10 by stromal cells during colorectal tumor development. Hum Pathol 2002;33:806-811.
5. Tokuhara T, Adachi M, Hashida H, et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2001;49:489-496.
6. Kristiansen G, Schluns K, Yongwei Y, et al. CD10 expression in non-small cell lung cancer. Anal Cell Pathol 2002;24:41-46.
7. Popnikolov NK, Ayala AG, Graves K, et al. Benign myoepithelial tumors of the breast have immunophenotypic characteristics similar to metaplastic matrix-producing and spindle cell carcinomas. Am J Clin Pathol 2003;120:161-167.
8. Kalof AN, Tam D, Beatty B, et al. Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol 2004;57:625-629.
9. Moritani S, Kushima R, Sugihara H, et al. Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections. Mod Pathol 2002;15:397-405.
10. Huang WB, Zhou XJ, Chen JY, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol 2005;35:245-250.
11. Tse GM, Tsang AK, Putti TC, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005;58:185-189.
12. Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 1997;80:1798-1802.
13. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002;161:1557-1565.
14. Makretsov NA, Huntsman DG, Nielsen TO, et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004;15:6143-6151.
15. De Wever O, Mareel M. Role of tissue stroma in cancer invasion. J Pathol 2003;200:29-47.
16. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-2392.
17. Atherton AJ, O'Hare MJ, Buluwela L, et al. Ectoenzyme regulation by phenotypically distinct fibroblast subpopulations isolated from the human mammary gland. J Cell Sci 1994;107:2931-2939.
18. Pan C, Cardarelli PM, Nieder MH, et al. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors. Cancer Res 2003;63:5526-5531.
19. West RB, Nuyten DS, Subramanian S, et al. Determination of stromal signatures in breast carcinoma. PLoS Biol 2005;3:1101-1110.
20. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
21. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423.